Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

BACKGROUND: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with the first presentation of symptoms, followed by a later ‘inflammatory’ phase which results in se...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Tania, Hoyo-Vadillo, Carlos, Adom, Akosua Agyeman, Favari-Perozzi, Liliana, Gastine, Silke, Dehbi, Hakim-Moulay, Villegas-Lara, Beatriz, Mateos, Eduardo, González, Yessica Sara Pérez, Navarro-Gualito, Maria D., Cruz-Carbajal, Alejandra S., Cortes-Vazquez, Miguel A., Bekker-Méndez, Carolina, Aguirre-Alvarado, Charmina, Aguirre-Gil, Gisela, Delgado-Pastelin, Lucero, Owen, Andrew, Lowe, David, Standing, Joseph, Escobedo, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306230/
https://www.ncbi.nlm.nih.gov/pubmed/35869526
http://dx.doi.org/10.1186/s13063-022-06533-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306230/
https://www.ncbi.nlm.nih.gov/pubmed/35869526
http://dx.doi.org/10.1186/s13063-022-06533-0

Ejemplares similares